Cargando…

Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer

Purpose: To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Donato, Vittorio, Arcangeli, Stefano, Monaco, Alessia, Caruso, Cristina, Cianciulli, Michele, Boboc, Genoveva, Chiostrini, Cinzia, Rauco, Roberta, Pressello, Maria Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831267/
https://www.ncbi.nlm.nih.gov/pubmed/24303369
http://dx.doi.org/10.3389/fonc.2013.00286
_version_ 1782291584428015616
author Donato, Vittorio
Arcangeli, Stefano
Monaco, Alessia
Caruso, Cristina
Cianciulli, Michele
Boboc, Genoveva
Chiostrini, Cinzia
Rauco, Roberta
Pressello, Maria Cristina
author_facet Donato, Vittorio
Arcangeli, Stefano
Monaco, Alessia
Caruso, Cristina
Cianciulli, Michele
Boboc, Genoveva
Chiostrini, Cinzia
Rauco, Roberta
Pressello, Maria Cristina
author_sort Donato, Vittorio
collection PubMed
description Purpose: To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemotherapy. Materials and Methods: Sixty-one consecutive patients considered non-progressive after two cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25–2.28 Gy each administered in 6 weeks up to a total dose of 67.5–68.4 Gy (range, 64.5–71.3 Gy). Thirty-two received sequential RT after two more cycles (total = 4 cycles) of chemotherapy, while 29 were treated with concurrent chemo-radiation. The target was considered the gross tumor volume and the clinically proven nodal regions, without elective nodal irradiation. Results: With a median follow up of 27 months (range 6–40), 1-year and 2-year OS rate for all patients was 77 and 53%, respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade ≥4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients. Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis. The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity. Conclusion: A moderately hypofractionated radiation course delivered with a Helical Intensity-Modulated Technique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time.
format Online
Article
Text
id pubmed-3831267
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38312672013-12-03 Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer Donato, Vittorio Arcangeli, Stefano Monaco, Alessia Caruso, Cristina Cianciulli, Michele Boboc, Genoveva Chiostrini, Cinzia Rauco, Roberta Pressello, Maria Cristina Front Oncol Oncology Purpose: To assess clinical outcomes and toxicities in patients with stage III unresectable non-small cell lung cancer (NSCLC) treated with a moderately escalated hypofractionated radiotherapy delivered with Helical Intensity-Modulated Technique in combination with sequential or concurrent chemotherapy. Materials and Methods: Sixty-one consecutive patients considered non-progressive after two cycles of induction chemotherapy were treated with a moderately escalated hypofractionated radiation course of 30 daily fractions of 2.25–2.28 Gy each administered in 6 weeks up to a total dose of 67.5–68.4 Gy (range, 64.5–71.3 Gy). Thirty-two received sequential RT after two more cycles (total = 4 cycles) of chemotherapy, while 29 were treated with concurrent chemo-radiation. The target was considered the gross tumor volume and the clinically proven nodal regions, without elective nodal irradiation. Results: With a median follow up of 27 months (range 6–40), 1-year and 2-year OS rate for all patients was 77 and 53%, respectively, with a median survival duration of 18.6 months in the sequential group and 24.1 months in the concomitant group. No Grade ≥4 acute and late toxicity was reported. Acute Grade 3 treatment-related pneumonitis was detected in 10% of patients. Two patients, both receiving the concurrent schedule, developed a Grade 3 acute esophagitis. The overall incidence of late Grade 3 lung toxicity was 5%. No patients experienced a Grade 3 late esophageal toxicity. Conclusion: A moderately hypofractionated radiation course delivered with a Helical Intensity-Modulated Technique is a feasible treatment option for patients with unresectable locally advanced NSCLC receiving chemotherapy (sequentially or concurrently). Hypofractionated radiotherapy with a dedicated technique allows safely dose escalation, minimizing the effect of tumor repopulation that may occur with prolonged treatment time. Frontiers Media S.A. 2013-11-18 /pmc/articles/PMC3831267/ /pubmed/24303369 http://dx.doi.org/10.3389/fonc.2013.00286 Text en Copyright © 2013 Donato, Arcangeli, Monaco, Caruso, Cianciulli, Boboc, Chiostrini, Rauco and Pressello. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Donato, Vittorio
Arcangeli, Stefano
Monaco, Alessia
Caruso, Cristina
Cianciulli, Michele
Boboc, Genoveva
Chiostrini, Cinzia
Rauco, Roberta
Pressello, Maria Cristina
Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_full Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_fullStr Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_full_unstemmed Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_short Moderately Escalated Hypofractionated (Chemo) Radiotherapy Delivered with Helical Intensity-Modulated Technique in Stage III Unresectable Non-Small Cell Lung Cancer
title_sort moderately escalated hypofractionated (chemo) radiotherapy delivered with helical intensity-modulated technique in stage iii unresectable non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831267/
https://www.ncbi.nlm.nih.gov/pubmed/24303369
http://dx.doi.org/10.3389/fonc.2013.00286
work_keys_str_mv AT donatovittorio moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT arcangelistefano moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT monacoalessia moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT carusocristina moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT cianciullimichele moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT bobocgenoveva moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT chiostrinicinzia moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT raucoroberta moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer
AT pressellomariacristina moderatelyescalatedhypofractionatedchemoradiotherapydeliveredwithhelicalintensitymodulatedtechniqueinstageiiiunresectablenonsmallcelllungcancer